Voquezna denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for voquezna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Voquezna as Non-Formulary

Voquezna (vonoprazan) is a newer class of acid blocker and may not yet appear on all UHC plan formularies, or may be placed on a non-preferred or excluded tier. A non-formulary denial is a coverage-structure decision, not a clinical judgment — it means UHC's benefit design favors lower-cost alternatives like PPIs. This can be appealed through a formulary exception process and, if necessary, a formal internal and external appeal.

## Start With a Formulary Exception Request

The fastest path to coverage is a formulary exception, which your prescriber submits directly to UHC. The exception is granted when the prescriber documents that no formulary alternative is clinically appropriate for this patient. The key arguments are:

• The patient has an established history of inadequate response to one or more formulary PPI alternatives (documented with dates and outcomes).
• The patient has a clinical reason — documented in the chart — why vonoprazan's distinct mechanism is necessary (e.g., CYP2C19 metabolism considerations, prior H. pylori treatment failure on PPI-based regimen).
• The patient cannot use a formulary alternative due to a documented clinical circumstance.

Your prescriber should obtain UHC's formulary exception criteria before submitting, so the letter addresses every listed requirement.

## Your Formal Appeal Rights

• Internal appeal (ERISA §503 / ACA): If the exception is denied, file a formal internal appeal within the deadline on the denial notice.
• External review (ACA §2719): After a final internal denial, you have approximately four months to request binding independent external review by an accredited IRO.
• Urgent/expedited track: Available when standard timelines create undue clinical risk.

## Documentation to Gather

1. Formulary alternatives tried — a dated list of every UHC-listed acid-suppressive alternative the patient has used, with duration, dose adjustments, and documented outcomes. 2. Clinical rationale for voquezna — prescriber letter explaining the mechanism distinction (PCAB vs. PPI) and why it is clinically relevant for this patient's specific situation, per the FDA label and applicable ACG guidance. 3. Diagnosis and diagnostic workup — endoscopy, H. pylori testing, or other objective evidence of the condition requiring treatment. 4. UHC formulary for the current plan year — identify the listed alternatives so the appeal letter addresses each one specifically. 5. FDA prescribing label for Voquezna — attach to support the approved indication and distinct pharmacology.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Supporting Documentation | |---|---| | Formulary alternative(s) tried | Dated medication history with outcomes | | Alternative(s) inadequate or inappropriate | Prescriber's clinical rationale; chart notes | | Medical necessity of vonoprazan | Diagnosis records; prescriber attestation | | Distinct mechanism relevant to this case | FDA label PCAB mechanism section |

Non-formulary exceptions succeed most often when the prescriber's letter is specific: name the alternatives, state what happened when they were tried, and explain why vonoprazan is not merely preferred but clinically necessary.